Story perspectives

Aurora Therapeutics Launches with $16M to Revolutionize Rare Disease Treatment

1/10/2026

28 3

Summary

Aurora Therapeutics Launch

Aurora Therapeutics officially launched to revolutionize gene editing for rare diseases.
Co-founders Jennifer Doudna, Nobel laureate, and Fyodor Urnov secured $16 million in seed funding from Menlo Ventures.
The company plans to use the FDA's plausible mechanism pathway to develop multiple therapies for conditions like phenylketonuria (PKU).
CEO Edward Kaye emphasized a scalable approach to address rare disease treatment challenges and reach millions of patients previously overlooked in genetic medicine.

Summary

Helmholtz Advances CRISPR

The Helmholtz Centre for Infection Research reports Cas12a3, a CRISPR mechanism that cleaves transfer RNA to inhibit protein production in infected cells.
This expands the CRISPR toolbox and suggests uses in diagnostics and treatments.
By combining Cas12a3 with other nucleases, researchers detected RNAs from multiple viruses, including influenza and SARS-CoV-2.
The team plans to explore Cas12a3 further and develop it for molecular diagnostics, highlighting bacterial defense systems.

1 of 2

Aurora Therapeutics Launch

Aurora Therapeutics officially launched to revolutionize gene editing for rare diseases.
Co-founders Jennifer Doudna, Nobel laureate, and Fyodor Urnov secured $16 million in seed funding from Menlo Ventures.
The company plans to use the FDA's plausible mechanism pathway to develop multiple therapies for conditions like phenylketonuria (PKU).
CEO Edward Kaye emphasized a scalable approach to address rare disease treatment challenges and reach millions of patients previously overlooked in genetic medicine.

1 / 2